Genetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer.

Ann Med · 2025 · PMC12444925 · PMID 40958617

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Our survival analysis implied that CYP2A6 intermediate/slow metabolizers may have a trend of lower risk of DFS events compared to normal metabolizers, although the result did not reach statistical significance in the multivariate analysis.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.